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Targeted radionuclide therapy is an alternative method of radiation treatment which uses a tumor-seeking agent carrying a ra-
dioactive atom to deposits of tumor, wherever in the body they may be located. Recent experimental data signiﬁes promise for the
amalgamation of gene transfer with radionuclide targeting. This review encompasses aspects of the integration of gene manipula-
tion and targeted radiotherapy, highlighting the possibilities of gene transfer to assist the targeting of cancer with low molecular
weight radiopharmaceuticals.
INTRODUCTION
While tumors which are conﬁned to their site of ori-
gin may often be cured by local treatment such as surgery
or conventional external beam irradiation, cancer which
has spread to locations distant from the primary tumor
requires a treatment which is applied to the whole body
of the patient. Total body irradiation is eﬀective in the
management of leukemia but normal tissue intolerance
restricts the radiation dose which can be given, so that it
cannot be used against less radiosensitive neoplasia. Bi-
ologically targeted radionuclide therapy is an alternative
method of systemic irradiation treatment which circum-
vents the two problems of widespread distribution of dis-
ease and the intolerance of normal tissues.
Targeted radiotherapy uses a molecular vehicle which
either localises on the surface of malignant cells or is pref-
erentially accumulated within them. For many tumours,
monoclonal antibodies or their fragments represent the
only targeting agents. With the notable exception of B-
cell lymphoma [1, 2], clinical applications of these ra-
diolabelled macromolecules have generally been unsatis-
factory due to low tumor speciﬁcity of targeted epitopes,
limited penetration into tumors, and the provocation of
anti-mouse immunoglobulin responses. These considera-
tions favour the use of nonimmunogenic small molecules
with higher uptake in tumours. These criteria are ful-
ﬁlled by peptides, meta-iodobenzylguanidine (MIBG),
and sodium iodide (NaI), which are readily available in
radioiodinated form. MIBG and NaI have been used ex-
tensively for the treatment of neural crest-derived tumors
(neuroblastoma and phaeochromocytoma) and thyroid
carcinoma, respectively.
The new challenge is to enhance targeted radiother-
apy by combining it with the transfer into tumour cells of
genes encoding speciﬁc transporters. The success of this
approach has been demonstrated in model systems. Ef-
forts are now underway to optimise tumour to normal
tissue uptake ratios; to limit the expression of transporter
genes to malignant sites; and to compare the therapeutic
potential of α-a n dβ-emitting radionuclides conjugated
to tumour-seeking agents. These investigations will de-
termine optimal promoter/transgene/radionuclide com-
binations for eﬀective human anticancer gene therapy.
TRANSDUCTION OF ANTIGEN ENCODING GENES
FOR ANTIBODY TARGETING
The eﬃcacy of radiolabelled antibodies is not due
to radiation kill alone [3] but results also from the cy-
totoxic eﬀects of unlabelled antibody, namely apoptosis,
complement-mediated cytolysis and antibody-dependent
cellular cytotoxicity. This type of treatment is proving
to be useful in the management of B-cell lymphomas
[4] which are more radiosensitive than solid tumours.
They have a propensity to apoptose after radiation in-
sult and have limited capacity for the repair of sublethal
damage. However, radioimmunotherapy of other tumour
types has been less impressive. An average value, com-
puted from a wide range of articles, for the accumula-
tion of radiolabelled antibodies—0.005% per gram of the
administered activity—is insuﬃcient for tumour sterili-
sation [5]. An impediment to radioimmunotherapy is the
sparsity of antigen presentation on the membranes of tu-
mour cells.
This problem has been addressed by transfection of
genes to induce tumour cells to express high concentra-
tions of membrane-associated epitopes which have aﬃn-
ity for monoclonal antibodies. Radiolabelled antibodies
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been used extensively in experimental and clinical de-
tection and treatment of various tumours (reviewed by
Buchsbaum and Curiel [6]). Raben et al [7]h a v ed e m o n -
stratedthatadenovirus-mediatedgenetransferresultedin
high levels of CEA expression in vitro in tumour cells that
did not constitutively express CEA, rendering those cells
capable of binding radiolabelled COL-1 anti-CEA anti-
body. They have further demonstrated the applicability
of this approach in vivo in nude mice resulting in en-
hanced, radiolabelled, antibody localisation to tumours
transduced by intratumoural injection of the recombi-
nant virus.
After extensive preclinical testing, the most exciting
clinical data has come from the use of radioimmunother-
apy in the treatment of lymphoma and haematological
malignancies and it would now appear highly likely that
radioimmunotherapy in combination with gene transfer
will play a major role in treatment strategies for these dis-
eases. Results in solid tumours are improving. However,
much progress remains to be made before RIT becomes a
component of standard practice for common malignan-
cies in the clinic.
FACILITATION OF PEPTIDE TARGETING
BY RECEPTOR GENE EXPRESSION
Tumour-targeting peptides oﬀer several advantages
over antibodies such as improved penetration character-
istics, ease of labelling, and lack of immunogenicity. Sev-
eral studies show the feasibility of inducing the expres-
sion of receptors by tumour cells to improve the accumu-
lation of toxic radionuclides transported by a variety of
peptide ligands. For example, virus-assisted gene transfer
stimulated the expression of the receptor for thyrotropin-
releasing hormone (TRH) with subsequent binding of ra-
diolabelled TRH [8]. Unfortunately, this tripeptide has
a short biological half-life in serum and loses receptor
aﬃnity after conjugation to radionuclides. Using in vitro
and in vivo models, Rogers et al [9] have demonstrated
the potential of a seven-peptide analogue of bombesin
to target tumour cells transfected with the gene encod-
ing gastrin releasing peptide receptor. This ligand is at-
tractive because it is readily bound to several diﬀerent ra-
dionuclides, maintains receptor binding aﬃnity and ex-
hibits in vivo stability. Recently, Stackhouse et al [10] in-
troduced a greater level of sophistication to this scheme
by placing the expression of the GPR transgene under
the control of promoter elements of one of two diﬀer-
ent genes—erbB-2 and MUC1—which are overexpressed
in a number of tumours. This strategy was successful in
restricting GPR expression to human breast and cholan-
giocarcinoma cell lines thereby demonstrating the poten-
tial for tumour-speciﬁc targeting with radiolabelled pep-
tide. An exciting application of the control of expression
by the MUC1 carcinoma-promoter has been described by
Chen et al[11].Theyeliminatedsixlogsofcontaminating
cancer cells from haemopoietic stem cell preparations by
ganciclovir treatment after adenoviral-mediated trans-
duction of HSV-tk gene under control of the MUC1 pro-
moter. This study illustrates the potential of the gene
transfer approach to the purging of marrow or peripheral
blood stem cells.
An attractive means of improving the speciﬁcity of
targeting is to express a nonhuman receptor on tumour
cells and target these with a xenogeneic molecule. For
example, the murine glycoprotein, interleukin-4 (IL-4),
doesnotbindtothehumanIL-4receptornordoesthehu-
manIL-4haveaﬃnityforthemurinereceptor.Themouse
receptor cDNA has been expressed in heterologous cells,
resulting in a ﬁve-fold increase in binding of ligand to
transfectants [12]. It is hoped that this promising strategy
for the transport of therapeutic radionuclides can be de-
veloped using xenogeneic systems which involve smaller
targeting agents such as peptides or steroids [13].
Somatostatin receptors, which are expressed on many
tumours of neuroendocrine origin, constitute another
peptide target which may be exploitable for radionuclide
therapy.Octreotideisanoctapeptideanalogueofsomato-
statin which has greater stability in plasma than the natu-
ralligand[14].Rogersetal[15]recentlyemployedrecom-
binant adenoviral vectors to induce somatostatin recep-
tors on human nonsmall cell lung cancer cells which were
grown as xenografts. Tumour localisation was demon-
strated using [111In]-labelled octreotide and therapeutic
eﬃcacy was obtained with [90Y] octreotide. This is the
ﬁrst illustration in vivo of the eﬀectiveness of a radiola-
beled peptide targeted to a receptor expressed on the sur-
face of tumor cells following gene transfer. It is expected
that these studies will form the basis of future therapeu-
tic investigations using gene transfer to enhance tumour
targeting by radiolabelled octreotide.
RADIOHALIDE CONCENTRATION VIA THE SODIUM
IODIDE SYMPORTER
Unlike the above schemes for radionuclide target-
ing, sodium radioiodide (Na131I) therapy requires no ra-
diochemicalsyntheticprocedure.Mostwell-diﬀerentiated
thyroid tumours retain iodide-concentrating capacity—
mediated by the sodium (Na) iodide (I) symporter (NIS).
Therefore, Na131I is used to ablate postsurgical remnants
and to treat recurrent and metastatic disease. The overall
prognosis following radioiodine therapy is good for dif-
ferentiated thyroid cancer. This is the most basic, yet most
eﬃcacious form of radionuclide therapy to date.
Cloning and characterisation of the sodium iodide
symporter (NIS) gene has stimulated cytoreductive gene
therapy based on NIS gene transfer followed by the ad-
ministration of radioiodide. Transfer of the NIS gene into
a variety of nonthyroidal cancer cell lines has induced io-
dide uptake activity and cytotoxicity [16, 17, 18]. Follow-
ing PSA promoter-mediated NIS gene delivery, prostate-
speciﬁc iodide accumulation was achieved in prostate
cancer cells that was suﬃcient to attain a therapeutic104 R. J. Mairs and M. Boyd 2003:2 (2003)
response of 131Ii nv i t r oa n di nv i v o[ 19, 20]. These ob-
servations indicate that, following thyroid blockade, it
may be possible to deliver Na131I to transfected, NIS-
expressing, tumour cells with minimal uptake of radioac-
tivity in normal tissues.
However, rapid eﬄux of radioiodide from NIS gene
transfectants imposes a severe limitation on tumor cell
killing. Means of circumventing this problem are under
investigation. Unlike NIS-transfected tumor cells, thyro-
cytes exhibit, in addition, peroxidase activity which is re-
sponsiblefortheoxidationofaccumulatediodide,leading
to its conjugation to tyrosyl residues of thyroglobulin and
prolonged entrapment within the cell. Huang et al [21]
reported an increase in radioiodide uptake and retention
and enhanced apoptosis in nonsmall cell lung cancer cells
transfected with both NIS and thyroperoxidase genes.
As well as iodide, several other monovalent anions
have the aﬃnity for NIS [22]. Those with ionic radii simi-
lar to iodide are more readily transported [23]. Of special
interestare[211At−]astatidefortherapyandpertechnetate
(99mTcO4
−) for imaging.
The choice of therapeutic radionuclide (Table 1)i s
inﬂuenced by the expected intracellular residence time
of the radioactivity and the range of cross ﬁre radia-
tion needed to sterilise clumps of tumor cells of diﬀer-
ent sizes. Ideally, the physical half-life of the radionu-
clide should closely match its intracellular half-time of re-
tention. Therefore, an alternative tactic to overcome the
rapid eﬄux of iodide from NIS transfectants is to em-
ploy radiohalides with short t1/2 values. Experimental ev-
idence indicates that the highly radiotoxic α-emitter as-
tatide (Na211At) has an aﬃnity for NIS-expressing cells
[24] and could be an alternative radiohalide to [131I]-
iodide for NIS-based endoradiotherapy.
The demonstration that NIS was expressed not only
in the lactating mammary gland but also in more than
80% of breast cancer [25] indicated that radioiodide may
be an option for the diagnosis and treatment of mam-
maryglandmalignancies.Toassessthefeasibilityofimag-
ing NIS-expressing tumors, we compared the rate of loss
of actively transported 131Ia n d99mTcO4
− in transduced
UVW human glioma cells (Figure 1). The enhanced re-
tention of 99mTcO4
− suggested its utility for scintigraphic
localisation of tumors after NIS-transfection. Recently,
Moon et al [26] established a correlation between the
expression of NIS mRNA and the uptake of 99mTcO4
−
in 25 breast tumors. Because of its chemical similarity
to pertechnetate, the perrhenate anion (188ReO4
−) is also
concentrated by NIS-positive cells. 188ReO4
− could be a
potenttherapeuticagentbecauseitisabletodeliveradose
4.5 times higher than 131I[ 27].
Exploitation of the NIS has potentially important ap-
plications in the management of breast cancer and other
tumor types. Future directions in NIS-targeting will in-
clude the enhancement of radiohalide retention in tu-
mors, circumvention of normal tissue uptake by diﬀeren-
tial regulation of NIS expression, and the investigation of
tumor-imaging agents.
Table 1. Radiohalogens for targeted radiotherapy.
Radionuclide Half-life Emitted particles Particle range
131I8 d β 0.8mm
125I6 0 d A u g e r e l e c t r o n s ∼ 10nm
123I1 3 h A u g e r e l e c t r o n s ∼ 10nm
211At 7h α 0.05mm
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Figure 1. Rate of iodide eﬄux from UVW-hNIS cells. 106 cells
were incubated with 7kBq/ml Na131Io rN a 99mTcO4
− for 1hour.
The radioactive solution was replaced with fresh medium which
was removed at various intervals for measurement of activity
by gamma counting. Each point represents the mean and S.D.
of three experiments performed in triplicate. Intracellular half-
times of retention: 131I = 3min; 99mTcO4
− = 8min.
TRANSFECTION OF THE NORADRENALINE
TRANSPORTER GENE FOR MIBG-
TARGETED RADIOTHERAPY
One impediment to the wider application of radioio-
dide therapy is the localisation of radioactivity in non-
target organs. This has prompted the search for tumor-
aﬃnic radiolabelled compounds which have a low ten-
dency to deiodinate in vivo. One such agent is [131I]-
labelled meta-iodobenzylguanidine ([131I]MIBG). The
structure of MIBG is based on those of the adrener-
gic neurone blockers guanethidine and bretylium [28]
(Figure 2). Because MIBG has high aﬃnity for the nora-
drenalinetransporter(NAT)[29],itisusedintheimaging
and treatment of tumors derived from the neural crest,
such as neuroblastoma and phaeochromocytoma. NAT
expression is predictive for MIBG uptake capacity [30]
and quantiﬁcation of NAT mRNA could be used for the
selection of patients for MIBG therapy [31].
Approximately 15% of neuroblastoma patients are
MIBG negative by scintigraphy and therefore do not
progress to [131I]MIBG therapy. Moreover, [131I]MIBG2003:2 (2003) Targeting Radiotherapy to Cancer by Gene Transfer 105
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Figure 2. Catecholamines, adrenergic neurone blockers, and MIBG.
uptake in malignant sites is heterogeneous [32], suggest-
ing that this therapy alone is unlikely to cure advanced
stage disease. Our eﬀorts to increase MIBG accumula-
tion in malignant cells have considered means of en-
hancing NAT gene transcription. Recently, we have trans-
fected the NAT gene into neuroblatoma cells, resulting in
stimulated MIBG uptake. Transfectants more readily suc-
cumbed in a dose-dependent manner to treatment with
[131I]MIBG [33]. While presently, there is only an in vitro
demonstration of the eﬀect, these results are promising
and indicate that it may be possible to elevate the in-
tracellular levels of the radiopharmaceutical so that cure,
rather than temporary control of tumour growth, could
betheoutcome.Givenanappropriatedeliveryvehicleand
tumour-speciﬁc control of expression, the introduction
of exogenous NAT may make more neuroblastoma tu-
mours amenable to MIBG therapy. In collaboration with
the Gaslini Institute, Genoa, we are currently develop-
ing immunoliposomal systems for the delivery to neurob-
lastoma of NAT cDNA and MIBG. [131I]MIBG is one of
the best agents for targeted radiotherapy but its utility is
restricted to a small number of NAT-expressing tumour
types.WeobservedthataftertransfectionoftheNATgene
into a human glioma cell line, it actively concentrated
[131I]MIBG resulting in substantial toxicity, demonstrat-
ing the potential of gene therapy-assisted MIBG-targeted
radiotherapy for the treatment of nonneuroectodermal
tumors [34]. These ﬁndings are extremely encourag-
ing for the development of NAT gene transfer-mediated
[131I]MIBG therapy. We expect the ﬁrst clinical appli-
cations to be in the treatment of glioma or prostate
carcinoma.
Targeting gene expression speciﬁcally to tumour cells,
is one of the most important goals of research in cancer
gene therapy. Appropriate control elements for the ex-
pressionoftransgenesthatfacilitatetargetedradiotherapy
are radiation-inducible gene promoters. Aspects of this
type of gene regulation are reviewed by Robson in this
issue.
Telomerase is the most common general marker of
cancer cells and its activity has been detected in every
major category of human malignancy, whereas normal
somatic tissues have negligible activity [35, 36, 37, 38].
Therefore, an alternative method of specifying gene ex-
pression to malignant cells is provided by the telom-
erase promoters. Unfortunately, mammalian promoter
elements are generally ineﬃcient transcriptional activa-
tors [39]. However, we observed 17-fold enhancement of
[131I]MIBG uptake by UVW glioma cells transfected with
the NAT gene whose expression was driven by the hu-
man telomerase RNA (hTR) promoter. This level of in-
duction was 70% of the uptake achieved by a strong vi-
ral promoter and was suﬃcient to sterilise all clonogens
in multicellular spheroids, suggesting that hTR-regulated
expressionofNATmaybeaneﬀectivetherapeuticstrategy
[40].
EVALUATION OF RADIOLOGICAL BYSTANDER
EFFECTS
It is unlikely that gene therapy technology will achieve
100% transfection of cells in a clinical tumour. Bystander
eﬀects are therefore an important requirement for eﬀec-
tive gene therapy. Current gene therapy is mostly based106 R. J. Mairs and M. Boyd 2003:2 (2003)
Figure 3. Radiation cross ﬁre. An advantage of the concentra-
tion in tumor cells of radionuclides with long-range emissions
(eg, 131I) is the presence of a radiological bystander eﬀect. That
is the bombardment of untargeted cells by beta decay particles
emanating from neighbouring, successfully targeted cells which
have actively accumulated 131I-labelled drug.
Figure 4. Transfectant mosaic spheroids. These multicellular
spheroids were prepared by mixing human glioma cells (UVW)
with UVW cells transfected with the gene encoding the jelly-
ﬁsh green ﬂuorescent protein (GFP). The GFP can be used as
a marker for the transfer of therapeutically useful genes such as
those encoding receptors for targeting agents. Spheroids com-
posed of a range of proportions of transfected to untransfected
cells allow the determination of the inﬂuence of gene transfer
eﬃciency upon the eﬃcacy of targeted radiotherapy.
on prodrug activation, with bystander eﬀects dependent
on gap junctions which often diminish with tumour
progression [41]. Novel systems providing a freely diﬀus-
able product are under investigation [42].
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Figure 5. The eﬀect on clonogenic survival of TMS treated
with [131I]MIBG. TMS composed of various proportions of
NAT-expressing cells were assessed for clonogenic potential af-
ter administration of [131I]MIBG. Spheroids were treated with
0t o6 M B q / m lo f[ 131I]MIBG before washing and leaving in-
tact for 24hours to allow radiation cross ﬁre to occur. The vari-
ous spheroid groups were then disaggregated to single cells and
seeded for clonogenic survival. The data is mean values of three
experiments with error bars showing standard deviations.
Multicellular spheroids are substantially more suscep-
tible than monolayer cultures to the lethal eﬀects of 131I
β-radiation [43]. The increased eﬀectiveness of radionu-
clide treatment of cellular aggregates is due to the en-
hanced eﬃciency of absorption of decay energy in three-
dimensional cultures [34, 44]. This cross ﬁre irradiation
phenomenon (Figure 3) is an especially attractive feature
of gene therapy schemes involving cellular concentration
of radionuclides since gene transfer is notoriously in-
eﬃcient, necessitating a mechanism which achieves by-
stander cell kill. The radiological bystander eﬀect result-
ing from radiation cross ﬁre provides exciting new pos-
sibilities, especially when transfection rates are low. This
and other bystander eﬀects require further investigation,
for which a suitable experimental model would be very
valuable.
Very recently, we have developed a modiﬁed spheroid
system—transfectant mosaic spheroids (TMS) [45]—
which is well suited to the experimental investigation
of bystander eﬀects (Figure 4). TMS are hybrids formed
by coculturing gene-transfected and nontransfected (but
otherwise identical) cells in controlled proportions. This
allows the experimental simulation of small tumours
in which a range of proportions of cells have been2003:2 (2003) Targeting Radiotherapy to Cancer by Gene Transfer 107
transfected. The mosaic spheroid model is used in our in-
vestigation of the radiological bystander eﬀect to quantify
the eﬀects of radiation cross ﬁre as a function of the pro-
portion of the cells transfected.
To examine the utility of this system, we prepared
TMS from glioma cells transfected with the NAT gene or
theGFPgene.Cellkillingby[131I]MIBGwasproportional
to the percentage of MIBG-uptaking cells (Figure 5). We
conclude that TMS provide a useful model for assessment
of the eﬀectiveness of targeted radiotherapy in combina-
tion with gene therapy when less than 100% of the target
cell population is expressing the NAT transgene [46].
CONCLUSION
Despite the attractiveness of the concept of sterilising
cancer cells by means of the speciﬁc delivery of radionu-
clides, targeted radiotherapy has been applied only to a
fewmalignantdiseaseswithsuitablebiochemicalfeatures.
Theadventofgenetransfertechnology,promisestowiden
the scope of targeted radiotherapy by enabling the expres-
sion by tumour cells of membrane-bound proteins which
actively accumulate radiopharmaceuticals.
Recent research ﬁndings augur well for the develop-
ment of gene transfer to enable the targeting of a variety
oftumourtypeswithlowmolecularweightradiopharma-
ceuticals.Itisenvisagedthatthisapproachcombinedwith
conventional therapeutic modalities, will improve cancer
treatment in the new century. The immediate goals are
to achieve eﬃcient, tumour-speciﬁc, gene expression and
eﬃcacy in animal models before proceeding to clinical
evaluation.
We envisage that the ﬁrst clinical usage of this com-
bined approach will be for the treatment of regionally
conﬁned malignancies such as glioma and bladder carci-
noma or for the purging of bone marrow or peripheral
blood stem cells prior to autologous rescue. To turn these
dreams into reality, we must now develop eﬃcient and
speciﬁc vectors for the delivery of therapeutic transgenes.
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